Business Builders
For 18 years, Truffle Capital has been creating and financing to success radical and disruptive innovations in two fields of expertise, Life Sciences and Information Technologies. These creations revolutionize their sectors and will become the tomorrow’s leaders.
Truffle Capital is the only European Fund to support its innovations from creation to commercial success.
BioMedTech
Truffle Capital works closely with the world's best 50 universities to select and transform their most significant inventions into major technological innovations, novel medical devices and effective drug treatments.
FinTech
In terms of Information technologies, Truffle Capital has focused in FinTechs since 2014. Thanks to its team of dedicated experts, Truffle is able to select products & services with underlying complex technologies (deep tech).
Last investments
WeGroup
Acasi
PraeXo
SmartPush
HoliStick Medical
ArteDrone
Skinosive
iPaidThat
PKMed
Monisnap
ShareGroop
BariaTek
News
All News
Abivax Turns Away Suitors as Lead Drug Starts Covid-19 Tests
Abivax, the French biotech embarking on tests of its lead experimental medicine for Covid-19, has turned away several suitors in recent months.
MEDEOR, Truffle Capital's new fund, qualified by institutional investors through the Tibi committee
Medeor is among the 24 new funds qualified by the committee of institutional investors set up following the Tibi report.
"19 Hours a day of COVID-19"
"19 Hours a day of COVID-19" live the quarantine with Hartmut J. Ehrlich and Philippe Pouletty. A Truffle Capital mini-serie
"19 Hours a day of COVID-19"
"19 Hours a day of COVID-19" live the quarantine with Hartmut J. Ehrlich and Philippe Pouletty. A Truffle Capital mini-serie
Investors Search for Promising Covid Cures
The race to develop vaccines and treatments to build immunity to the novel coronavirus ...
Abivax Stock Soars as French Regulator Approves Testing of a Drug to Treat Covid-19
The French biotech company Abivax announced Thursday that it had received clearance from French regulators to begin a 1,000 patient trial ...